Biologics and Conjugates CDMO Services
As a subsidiary of Porton Pharma Solutions, a globally recognized CDMO, Porton Biologics and Conjugates CDMO Platform offers comprehensive, one-stop drug development and manufacturing services for biologics and conjugates, including ADCs, AOCs, PDCs, RDCs and more.
150+
Scientists
50+
Projects (IND/P1/P2/P3/NDA)
40+
Customers
Our Services
Conjugates
-
ADC
Antibody-Drug Conjugate -
AOC
-
PDC
-
PRC
-
SMDC
Targeting-vehicle
Antibody
Peptide
Small Molecule
Linker
Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
Lys (-NH2): Activated Acid(CO-OSu, etc.)
Short Peptide (VC, GFGG, etc.)
PEG
Click Chemistry
pH-Sensitivity (HN-CH2-O-, C+N-NH=CO-, Hydrazine, Carbonate)
Multi Branches
Payload
Cytotoxic Drugs
Oligonucleotides
Radionuclides
Fluorescers
Early Stage Development
mg ~ g Scale Library
Developability Assessment
Process Development
Payload-Linker Process Development
Targeting-vehicle Process Development
Bioconjugation and Purification Process Development
DP Formulation & Process Development
Manufacturing
Payload-Linker Manufacturing
Targeting-vehicle Manufacturing
DS Manufacturing
DP Manufacturing
Anynitical Development and QC
Analytical Method Development & Validation
Release Testing
Stability Study
Registration Services
CMC Filing Dossier
Supporting and Communication During Filing Process
-
ADC
Antibody-Drug Conjugate
-
AOC
-
PDC
-
PRC
-
SMDC
Antibody
Peptide
Small Molecule
Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
Lys (-NH2): Activated Acid(CO-OSu, etc.)
Short Peptide (VC, GFGG, etc.)
PEG
Click Chemistry
pH-Sensitivity (HN-CH2-O-, C+N-NH=CO-, Hydrazine, Carbonate)
Multi Branches
Cytotoxic Drugs
Oligonucleotides
Radionuclides
Fluorescers
mg ~ g Scale Library
Developability Assessment
Payload-Linker Process Development
Targeting-vehicle Process Development
Bioconjugation and Purification Process Development
DP Formulation & Process Development
Payload-Linker Manufacturing
Targeting-vehicle Manufacturing
DS Manufacturing
DP Manufacturing
Analytical Method Development & Validation
Release Testing
Stability Study
CMC Filing Dossier
Supporting and Communication During Filing Process
Porton Sites
Cranbury, New Jersey
- Payload-Linker (10-100 L, OEB 4 & 5)
- Bioconjugation (200-500 L, OEB 5)
- Pre-clinical to Commercial
Minhang, Shanghai
- OEB 4 &5
- 50 L
- Pre-clinical to Tox Batch
Fengxian, Shanghai
- OEB 4 & 5
- 200 L
- Phase I to Commercial
Pudong, Shanghai
- Antibody (200-500 L)
- Bioconjugation (10-200 L, OEB 5)
- Phase I to Phase II
Case Studies
More
Preformulation Strategy- Inception to Completion
Drug discovery is an exceedingly complex process. Discovering a new chemical entity is in itself a huge accomplishment, which is often possible only after almost two decades of hard experimental work as well as advanced simulation efforts. Therefore, the next stage of the process, determination of toxicity becomes even more crucial as most new chemical entities (NCE) are disqualified if the NCE shows a potential toxic effect, despite any possible therapeutic effect.
More
Facilitating PROTAC Drugs Development with Innovative Processes
The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.
More
